Global Access to Radiation Medicine: Key Findings of the Lancet Commission Report

Mary Gospodarowicz MD FRCPC FRCR(Hon)

Princess Margaret Cancer Centre, University of Toronto Union for International Cancer Control

28-29 September 2016

2016 IAEA Scientific Forum


Nuclear Technology for the Sustainable Development Goals



Predicted Global Cancer Cases

Cases (millions)





Source: WHO GloboCan


The Equity Gap

International Agency for Research on Cancer

- Availability of care
- Affordability of care
- Awareness Education, stigma
 "Know Do Gap"

Essential services for cancer

- Diagnostic services
 - Pathology, laboratory medicine
 - Imaging
- Surgery
- Radiotherapy
- Chemotherapy
- Palliative care



GLOBOCAN 2012 (IARC)

Dr. Tabaré Vázquez Honorary Chair:

Radiation oncologist and President of the Oriental Republic of Uruguay.

Task Force Members from over 35 Countries

GTFRCC - Secretariat



David Jaffray Princess Margaret Head of Secretariat



Mary Gospodarowicz Princess Margaret Immediate Past President, UICC



Eduardo Rosenblatt Applied Radiobiology and Radiotherapy Division IAEA



Bhadrasain Vikram Clinical Radiation Oncology Branch National Cancer Institute



Michael Barton Radiation Oncology University of New South Wales



Michael Baumann Radiation Oncology Technische Universität Dresden



Yolande Lievens Radiation Oncology Belgium, President-Elect ESTRO



Felicia M. Knaul Harvard Global Equity Initiative Boston



Rifat Atun Global Health Systems Cluster Harvard TH Chan School of Public Health



Cary Adams
Chief Executive Officer,
UICC




Julie Torode Deputy Chief Executive Officer UICC





Jake Van Dyk Western University

Global Access to Radiotherapy



Radiotherapy Demand vs. Coverage






Benefits of Radiotherapy vs. Costs

	Health benefits in life years saved (2015-2035; discounted)	
Low income	6.3 million	
Lower-middle income	9.9 million	
Upper-middle income	10.7 million	
Total	26.9 million	

	Nominal Model	Efficiency model	
Low income	\$26.6 Bn	\$14.1 Bn	
Lower-middle income	\$62.6 Bn	\$33.3 Bn	
Upper-middle income	\$94.8 Bn	\$49.4 Bn	
Total	\$184.0 Bn	\$96.8 Bn	

Radiotherapy – Return on Investment



Cohort Year

How many resources will we need in 20 years from now?

	High-income countries	Upper-middle- income countries	Lower- middle- income countries	Low-income counties
Fractions	76 424 000	77 014 000	40 974 000	13 268 000
Radiotherapy departments	4600	3700	2000	600
Megavoltage machines	9200	7400	3900	1300
CT scanners	4600	3700	2000	600
Radiation oncologists to be trained	15500	16800	9900	3300
Medical physicists to be trained	17 200	12 500	7200	2400
Radiation technologists to be trained	51900	45300	24900	8100

Action 1: population-based cancer control plans

Radiotherapy must be incorporated into population-based comprehensive cancer plans in all countries with explicit targets for scaling up radiotherapy capacity to expand coverage.

Target: by 2020, 80% of the countries should have cancer plans that include radiotherapy.

Action 2: expansion of access to radiotherapy

We urge immediate action to establish additional radiotherapy capacity by creating at least one cancer centre in each low-income and middle-income country by 2020. In addition to providing treatments, these new centres should be used to train the radiotherapy workforce to enable further expansion of radiotherapy coverage.

Target: an increase of 25% in the 2015 radiotherapy treatment capacity by 2025.

Action 3: human resources for radiotherapy

We call for new approaches to train radiotherapy professionals globally, with the creation of new core curriculums, innovative learning methods, and international credentialing to expand the radiotherapy workforce. Training should become part of the mandate of each national radiotherapy centre to self-propagate the required skills, enabling national expansion of cancer therapies and providing the ability to replace staff as they leave or are recruited out of country.

Target: 7500 radiation oncologists, 20 000 radiation technologists, and 6000 medical physicists to be trained in low-income and middle-income countries by 2025.

Action 4: sustainable financing to expand access to radiotherapy

Domestic and international financing will be needed to expand radiotherapy capacity with substantial upfront investment. International development banks and the private sector should work in partnerships with countries to finance investments in infrastructure and radiotherapy services.

Target: \$46 billion of investment by 2025 to establish radiotherapy infrastructure and training in low-income and middle-income countries.

Action 5: align radiotherapy access with universal health coverage

We call for inclusion of radiotherapy coverage in each country's universal health coverage plans to prevent catastrophic out-of-pocket expenditures and treatment abandonment.

Target: 80% of low-income and middle-income countries to include radiotherapy services as part of their universal health coverage by 2020.

Conclusions

- The cancer epidemic will lead to a substantial increase in radiotherapy indications from 7 to 12 million by 2035
- Radiotherapy is a critical and inseparable component of comprehensive cancer treatment. It is an effective treatment modality providing 2.5 million local controls and saving 1 million life years each year.
- Yet, in planning and building capacity for cancer, it is frequently the last resource to be considered. Therefore, worldwide access to radiotherapy is unacceptably low and there are important inequalities in access to radiotherapy.
- Investing in capital and human resources is needed

Fresh Thinking Required

- Our results provide compelling evidence that investment in radiotherapy not only enables treatment of large numbers of cancer cases to save lives, but also brings positive economic benefits
- Therefore we need fresh approaches:
 - Innovation in the technology efficiency, adaptability
 - Investment to respond to the scale of the need
 - Regulation for quality and safety
 - Financing
 - Sustainability of investment
 - Education and training

Acknowledgements

- Members of the Global Task Force for Cancer Control
- Authors of the Lancet Oncology Commission for Global Radiotherapy -R Atun, DA Jaffray, MB Barton, F Bray, M Baumann, B Vikram, TP Hanna, FM Knaul, Y Lievens, T Lui, M Milosevic, B O'Sullivan, DL Rodin, E Rosenblatt, J Van Dyk, ML Yap, E Zubizarreta, M Gospodarowicz.









THE LANCET Oncology







Thank you!

2016 IAEA Scientific Forum

Nuclear Technology for the Sustainable Development Goals

